Literature DB >> 27928146

Clinical Significance of Hematuria in Atrial Fibrillation With Oral Anticoagulation Therapy.

Hee Tae Yu1, Tae-Hoon Kim, Jae-Sun Uhm, Jong-Youn Kim, Hui-Nam Pak, Moon-Hyoung Lee, Boyoung Joung.   

Abstract

BACKGROUND: Hematuria is a common and important complication in atrial fibrillation (AF) patients on oral anticoagulation therapy (OAT). This study evaluated the clinical significance of hematuria and its relationship with genitourinary disease in AF patients receiving OAT.Methods and 
Results: Among 20,456 consecutive AF patients who visited a tertiary hospital from January 2005 to April 2015, 5,833 had hematuria. Of these 5,833 patients, 3,798 were on OAT (OAT(+) group) and 2,035 were not (OAT(-) group). A total of 1,785 patients from each group were then matched on propensity score analysis. The prevalence of cancer and other diseases in the genitourinary tract was evaluated. While there was no difference in the prevalence of genitourinary stones or urinary tract infection, genitourinary cancer was significantly more common in the OAT(+) group than in the OAT(-) group (1.6% vs. 0.7%, P=0.011). Bladder cancer was the most common genitourinary malignancy, and it was significantly more common in the OAT(+) group (1.2% vs. 0.5%, P=0.019). Subjects on warfarin were more likely to have bladder cancers of lower pathologic grade (63.6% vs. 33.3%, P=0.124).
CONCLUSIONS: OAT was associated with a higher prevalence and early detection of genitourinary cancer in AF patients with hematuria. Meticulous evaluation of the cause of hematuria is necessary in AF patients with hematuria receiving OAT.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27928146     DOI: 10.1253/circj.CJ-16-0917

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  7 in total

1.  Increasing use of anticoagulants in Germany and its impact on hospitalization rates for genitourinary bleeding.

Authors:  Olga von Beckerath; Alexander Matthias Paulitschek; Knut Kröger; Bernd Kowall; Frans Santosa; Andreas Stang
Journal:  J Thromb Thrombolysis       Date:  2020-05       Impact factor: 2.300

2.  Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation.

Authors:  Chun-Li Wang; Victor Chien-Chia Wu; Yu-Tung Huang; Yu-Ling Chen; Pao-Hsien Chu; Chang-Fu Kuo; Ming-Shien Wen; Shang-Hung Chang
Journal:  J Thromb Thrombolysis       Date:  2021-01       Impact factor: 2.300

Review 3.  The Investigation of Hematuria.

Authors:  Christian Bolenz; Bernd Schröppel; Andreas Eisenhardt; Bernd J Schmitz-Dräger; Marc-Oliver Grimm
Journal:  Dtsch Arztebl Int       Date:  2018-11-30       Impact factor: 5.594

4.  The association between new onset atrial fibrillation and incident cancer-A nationwide cohort study.

Authors:  Chi-Sheng Hung; Chia-Hsuin Chang; Jou-Wei Lin; Yi-Lwun Ho; Ming-Fong Chen
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

5.  2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary.

Authors:  Tze-Fan Chao; Boyoung Joung; Yoshihide Takahashi; Toon Wei Lim; Eue-Keun Choi; Yi-Hsin Chan; Yutao Guo; Charn Sriratanasathavorn; Seil Oh; Ken Okumura; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2021-11-13       Impact factor: 5.249

6.  Rivaroxaban in acute venous thromboembolism: UK prescribing experience.

Authors:  Victoria Speed; Jignesh P Patel; Derek Cooper; Stephen Miller; Lara N Roberts; Raj K Patel; Roopen Arya
Journal:  Res Pract Thromb Haemost       Date:  2021-10-21

7.  New Cancer Diagnosis After Bleeding in Anticoagulated Patients With Atrial Fibrillation.

Authors:  Sergio Raposeiras Roubín; Emad Abu Assi; Cristina Barreiro Pardal; María Cespón Fernandez; Isabel Muñoz Pousa; Rafael Cobas Paz; Jose Antonio Parada; Marta Represa Montenegro; María Melendo Miu; Sonia Blanco Prieto; Xavier Rosselló; Borja Ibañez; Andrés Íñiguez Romo
Journal:  J Am Heart Assoc       Date:  2020-11-03       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.